Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. ADAR1 compound C12
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. ADAR1 compound C12: sourced facts only. name: "In summary, C12 has been identified as a promising ADAR1 inhibitor for prostate cancer treatment." [PMID:40632646]; target: "In summary, C12 has been identified as a promising ADAR1 inhibitor for prostate cancer treatment." [PMID:40632646]; developer: "State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China." [PMID:40632646]; stage: "In vivo studies showed that C12 safely and effectively inhibited tumor growth in DU-145 and 22Rv1 xenograft models." [PMID:40632646]
02
Targets
ADAR (Adenosine deaminases acting on RNA (ADAR) family)
Beyond the preview
Go deeper on China Pharma Univ. ADAR1 compound C12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. ADAR1 compound C12.